<p>不幸的是，對於一些股東來説，<strong>Cresco Labs Inc.</strong>（CSE:CL）的股價在過去三十天內暴跌了 37%，延續了近期的痛苦。在過去的 30 天裏，股價的下跌使得股東們經歷了艱難的一年，股價在此期間下跌了 37%。</p>
<p>在價格大幅下跌之後，Cresco Labs 目前可能發出看漲信號，其市銷率（&#34;P/S&#34;）為 0.4 倍，因為在加拿大製藥行業中，幾乎一半的公司市銷率超過 1 倍，甚至市銷率高於 3 倍的情況也並不罕見。儘管如此，我們需要更深入地挖掘，以確定降低的市銷率是否有合理的依據。</p>
<p>特朗普承諾要&#34;釋放&#34;美國的石油和天然氣，這 15 只美國股票的發展有望受益。</p>
<p>查看我們對 Cresco Labs 的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/273639073-ps-multiple-vs-industry-1-dark-2/1764162132640?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/273639073-ps-multiple-vs-industry-1-dark-2/1764162132640"/></p>
<p>CNSX:CL 市銷率與行業比較 2025 年 11 月 26 日</p>
<h3>Cresco Labs 最近的表現如何？</h3>
<p>儘管該行業最近經歷了收入增長，但 Cresco Labs 的收入卻出現了下滑，這並不好。市銷率可能較低是因為投資者認為這種糟糕的收入表現不會有所改善。如果你仍然喜歡這家公司，你會希望情況不是這樣，以便你可以在它不受歡迎時買入一些股票。</p>
<p>想要了解分析師對公司的完整預測嗎？那麼我們 <strong>免費的</strong>Cresco Labs 報告將幫助你揭示未來的趨勢。</p>
<h2>Cresco Labs 是否有收入增長的預測？</h2>
<p>Cresco Labs 的市銷率對於一家預計僅能實現有限增長的公司來説是典型的，重要的是，其表現還低於行業水平。</p>
<p>在回顧過去一年的財務數據時，我們感到沮喪，因為公司的收入下降了 9.8%。過去三年的表現也不理想，因為公司總共縮減了 21% 的收入。因此，可以公平地説，最近的收入增長對公司來説是不可取的。</p>
<p>展望未來，預計未來三年每年將實現 0.4% 的增長，這是八位分析師對公司的估計。同時，行業的其餘部分預計每年將擴張 5.8%，這顯然更具吸引力。</p>
<p>根據這些信息，我們可以理解為什麼 Cresco Labs 的市銷率低於行業水平。似乎大多數投資者預計未來增長有限，因此只願意為該股票支付較低的價格。</p>
<h2>我們可以從 Cresco Labs 的市銷率中學到什麼？</h2>
<p>Cresco Labs 的市銷率隨着其股價的下跌而下降。一般來説，我們傾向於將市銷率的使用限制在評估市場對公司整體健康狀況的看法上。</p>
<p>我們已經確定 Cresco Labs 維持其低市銷率是因為其預測增長低於更廣泛的行業，正如預期的那樣。在這個階段，投資者認為收入改善的潛力不足以證明更高的市銷率。除非這些條件改善，否則它們將繼續對股價形成障礙。</p>
<p>始終需要考慮投資風險的潛在威脅。我們已經識別出 <strong>Cresco Labs 的兩個警告信號</strong>，理解這些應該成為你投資過程的一部分。</p>
<p>如果你對盈利的強大公司感興趣，那麼你會想查看這份 <strong>免費的</strong> 有趣公司名單，這些公司交易的市盈率較低（但已證明它們能夠實現盈利增長）。</p>

CRLBF

<p>Cresco Labs Inc. (CSE:CL) 的股價在過去 30 天內下跌了 37%，反映出收入表現不佳和有限的增長前景。該公司的市銷率為 0.4 倍，低於行業水平，顯示出投資者的擔憂。分析師預測 Cresco Labs 的增長有限，這導致其股票估值下降。由於收入趨勢疲軟以及與行業相比的較低增長預期，投資者變得謹慎</p>

<p>Unfortunately for some shareholders, the <strong>Cresco Labs Inc.</strong> (CSE:CL) share price has dived 37% in the last thirty days, prolonging recent pain. The drop over the last 30 days has capped off a tough year for shareholders, with the share price down 37% in that time.</p>
<div class="lb-trans"><p>不幸的是，對於一些股東來説，<strong>Cresco Labs Inc.</strong>（CSE:CL）的股價在過去三十天內暴跌了 37%，延續了近期的痛苦。在過去的 30 天裏，股價的下跌使得股東們經歷了艱難的一年，股價在此期間下跌了 37%。</p>
</div><p>Following the heavy fall in price, Cresco Labs may be sending bullish signals at the moment with its price-to-sales (or &#34;P/S&#34;) ratio of 0.4x, since almost half of all companies in the Pharmaceuticals industry in Canada have P/S ratios greater than 1x and even P/S higher than 3x are not unusual. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the reduced P/S.</p>
<div class="lb-trans"><p>在價格大幅下跌之後，Cresco Labs 目前可能發出看漲信號，其市銷率（&#34;P/S&#34;）為 0.4 倍，因為在加拿大製藥行業中，幾乎一半的公司市銷率超過 1 倍，甚至市銷率高於 3 倍的情況也並不罕見。儘管如此，我們需要更深入地挖掘，以確定降低的市銷率是否有合理的依據。</p>
</div><p>Trump has pledged to &#34;unleash&#34; American oil and gas and these 15 US stocks have developments that are poised to benefit.</p>
<div class="lb-trans"><p>特朗普承諾要&#34;釋放&#34;美國的石油和天然氣，這 15 只美國股票的發展有望受益。</p>
</div><p>See our latest analysis for Cresco Labs</p>
<div class="lb-trans"><p>查看我們對 Cresco Labs 的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/273639073-ps-multiple-vs-industry-1-dark-2/1764162132640" alt="" original-src="https://images.simplywall.st/asset/chart/273639073-ps-multiple-vs-industry-1-dark-2/1764162132640"/></p>
<p>CNSX:CL Price to Sales Ratio vs Industry November 26th 2025</p>
<div class="lb-trans"><p>CNSX:CL 市銷率與行業比較 2025 年 11 月 26 日</p>
</div><h3>How Has Cresco Labs Performed Recently?</h3>
<div class="lb-trans"><h3>Cresco Labs 最近的表現如何？</h3>
</div><p>While the industry has experienced revenue growth lately, Cresco Labs' revenue has gone into reverse gear, which is not great. The P/S ratio is probably low because investors think this poor revenue performance isn't going to get any better. If you still like the company, you'd be hoping this isn't the case so that you could potentially pick up some stock while it's out of favour.</p>
<div class="lb-trans"><p>儘管該行業最近經歷了收入增長，但 Cresco Labs 的收入卻出現了下滑，這並不好。市銷率可能較低是因為投資者認為這種糟糕的收入表現不會有所改善。如果你仍然喜歡這家公司，你會希望情況不是這樣，以便你可以在它不受歡迎時買入一些股票。</p>
</div><p>Want the full picture on analyst estimates for the company? Then our <strong>free</strong> report on Cresco Labs will help you uncover what's on the horizon.</p>
<div class="lb-trans"><p>想要了解分析師對公司的完整預測嗎？那麼我們 <strong>免費的</strong>Cresco Labs 報告將幫助你揭示未來的趨勢。</p>
</div><h2>Is There Any Revenue Growth Forecasted For Cresco Labs?</h2>
<div class="lb-trans"><h2>Cresco Labs 是否有收入增長的預測？</h2>
</div><p>Cresco Labs' P/S ratio would be typical for a company that's only expected to deliver limited growth, and importantly, perform worse than the industry.</p>
<div class="lb-trans"><p>Cresco Labs 的市銷率對於一家預計僅能實現有限增長的公司來説是典型的，重要的是，其表現還低於行業水平。</p>
</div><p>In reviewing the last year of financials, we were disheartened to see the company's revenues fell to the tune of 9.8%. The last three years don't look nice either as the company has shrunk revenue by 21% in aggregate. Therefore, it's fair to say the revenue growth recently has been undesirable for the company.</p>
<div class="lb-trans"><p>在回顧過去一年的財務數據時，我們感到沮喪，因為公司的收入下降了 9.8%。過去三年的表現也不理想，因為公司總共縮減了 21% 的收入。因此，可以公平地説，最近的收入增長對公司來説是不可取的。</p>
</div><p>Turning to the outlook, the next three years should generate growth of 0.4% each year as estimated by the eight analysts watching the company. Meanwhile, the rest of the industry is forecast to expand by 5.8% per year, which is noticeably more attractive.</p>
<div class="lb-trans"><p>展望未來，預計未來三年每年將實現 0.4% 的增長，這是八位分析師對公司的估計。同時，行業的其餘部分預計每年將擴張 5.8%，這顯然更具吸引力。</p>
</div><p>With this information, we can see why Cresco Labs is trading at a P/S lower than the industry. It seems most investors are expecting to see limited future growth and are only willing to pay a reduced amount for the stock.</p>
<div class="lb-trans"><p>根據這些信息，我們可以理解為什麼 Cresco Labs 的市銷率低於行業水平。似乎大多數投資者預計未來增長有限，因此只願意為該股票支付較低的價格。</p>
</div><h2>What We Can Learn From Cresco Labs' P/S?</h2>
<div class="lb-trans"><h2>我們可以從 Cresco Labs 的市銷率中學到什麼？</h2>
</div><p>Cresco Labs' P/S has taken a dip along with its share price. Generally, our preference is to limit the use of the price-to-sales ratio to establishing what the market thinks about the overall health of a company.</p>
<div class="lb-trans"><p>Cresco Labs 的市銷率隨着其股價的下跌而下降。一般來説，我們傾向於將市銷率的使用限制在評估市場對公司整體健康狀況的看法上。</p>
</div><p>We've established that Cresco Labs maintains its low P/S on the weakness of its forecast growth being lower than the wider industry, as expected. At this stage investors feel the potential for an improvement in revenue isn't great enough to justify a higher P/S ratio. Unless these conditions improve, they will continue to form a barrier for the share price around these levels.</p>
<div class="lb-trans"><p>我們已經確定 Cresco Labs 維持其低市銷率是因為其預測增長低於更廣泛的行業，正如預期的那樣。在這個階段，投資者認為收入改善的潛力不足以證明更高的市銷率。除非這些條件改善，否則它們將繼續對股價形成障礙。</p>
</div><p>It's always necessary to consider the ever-present spectre of investment risk. We've identified <strong>2 warning signs with Cresco Labs</strong>, and understanding these should be part of your investment process.</p>
<div class="lb-trans"><p>始終需要考慮投資風險的潛在威脅。我們已經識別出 <strong>Cresco Labs 的兩個警告信號</strong>，理解這些應該成為你投資過程的一部分。</p>
</div><p>If strong companies turning a profit tickle your fancy, then you'll want to check out this <strong>free</strong> list of interesting companies that trade on a low P/E (but have proven they can grow earnings).</p>
<div class="lb-trans"><p>如果你對盈利的強大公司感興趣，那麼你會想查看這份 <strong>免費的</strong> 有趣公司名單，這些公司交易的市盈率較低（但已證明它們能夠實現盈利增長）。</p>
</div>

Cresco Labs Inc. (CSE:CL) 對於某些投資者而言表現不佳，其股價下跌了 37%